scholarly journals Glucose Sensing in the Subcutaneous Tissue: Attempting to Correlate the Immune Response with Continuous Glucose Monitoring Accuracy

2018 ◽  
Vol 20 (5) ◽  
pp. 321-324 ◽  
Author(s):  
Jeffrey I Joseph ◽  
Gabriella Eisler ◽  
David Diaz ◽  
Abdurizzagh Khalf ◽  
Channy Loeum ◽  
...  
Keyword(s):  
Immune Response ◽  
Continuous Glucose Monitoring ◽  
Subcutaneous Tissue ◽  
Glucose Monitoring ◽  
Glucose Sensing ◽  
Monitoring Accuracy

scholarly journals Continuous Glucose Monitoring Accuracy Results Vary between Assessment at Home and Assessment at the Clinical Research Center

2012 ◽  
Vol 6 (5) ◽  
pp. 1103-1106 ◽  
Author(s):  
Yoeri M. Luijf ◽  
Angelo Avogaro ◽  
Carsten Benesch ◽  
Daniela Bruttomesso ◽  
Claudio Cobelli ◽  
...  
Keyword(s):  
Clinical Research ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Research Center ◽  
Clinical Research Center ◽  
Monitoring Accuracy ◽  
At Home

scholarly journals Accuracy of flash glucose monitoring and continuous glucose monitoring technologies: Implications for clinical practice

2018 ◽  
Vol 15 (3) ◽  
pp. 175-184 ◽  
Author(s):  
Ramzi A Ajjan ◽  
Michael H Cummings ◽  
Peter Jennings ◽  
Lalantha Leelarathna ◽  
Gerry Rayman ◽  
...  
Keyword(s):  
Continuous Glucose Monitoring ◽  
Diabetes Care ◽  
Interstitial Fluid ◽  
Glucose Monitoring ◽  
Relative Difference ◽  
Glucose Sensing ◽  
Sensor Data ◽  
Flash Glucose Monitoring ◽  
Fluid Sensor ◽  
Monitoring Technologies

Continuous glucose monitoring and flash glucose monitoring technologies measure glucose in the interstitial fluid and are increasingly used in diabetes care. Their accuracy, key to effective glycaemic management, is usually measured using the mean absolute relative difference of the interstitial fluid sensor compared to reference blood glucose readings. However, mean absolute relative difference is not standardised and has limitations. This review aims to provide a consensus opinion on assessing accuracy of interstitial fluid glucose sensing technologies. Mean absolute relative difference is influenced by glucose distribution and rate of change; hence, we express caution on the reliability of comparing mean absolute relative difference data from different study systems and conditions. We also review the pitfalls associated with mean absolute relative difference at different glucose levels and explore additional ways of assessing accuracy of interstitial fluid devices. Importantly, much data indicate that current practice of assessing accuracy of different systems based on individualised mean absolute relative difference results has limitations, which have potential clinical implications. Healthcare professionals must understand the factors that influence mean absolute relative difference as a metric for accuracy and look at additional assessments, such as consensus error grid analysis, when evaluating continuous glucose monitoring and flash glucose monitoring systems in diabetes care. This in turn will ensure that management decisions based on interstitial fluid sensor data are both effective and safe.

scholarly journals Effect of Continuous Glucose Monitoring Accuracy on Clinicians’ Retrospective Decision Making in Diabetes

2015 ◽  
Vol 9 (5) ◽  
pp. 1092-1102 ◽  
Author(s):  
Zeinab Mahmoudi ◽  
Mette Dencker Johansen ◽  
Hanne Holdflod Nørgaard ◽  
Steen Andersen ◽  
Ulrik Pedersen-Bjergaard ◽  
...  
Keyword(s):  
Decision Making ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Monitoring Accuracy

Comparison of subcutaneous and intravenous continuous glucose monitoring accuracy in an operating room and an intensive care unit

2015 ◽  
Vol 19 (2) ◽  
pp. 159-166 ◽  
Author(s):  
Masaya Munekage ◽  
Tomoaki Yatabe ◽  
Masahiko Sakaguchi ◽  
Hiroyuki Kitagawa ◽  
Takahiko Tamura ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Operating Room ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Monitoring Accuracy

scholarly journals Comparison of Continuous Glucose Monitoring Accuracy Between Abdominal and Upper Arm Insertion Sites

2019 ◽  
Vol 21 (5) ◽  
pp. 295-302 ◽  
Author(s):  
Isabelle Isa Kristin Steineck ◽  
Zeinab Mahmoudi ◽  
Ajenthen Ranjan ◽  
Signe Schmidt ◽  
John Bagterp Jørgensen ◽  
...  
Keyword(s):  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Upper Arm ◽  
Monitoring Accuracy ◽  
Insertion Sites

74-LB: Sudden Changes in Interstitial Glucose Sensing by Remote Real-Time Continuous Glucose Monitoring as a Marker of Hypoperfusion in Critically-Ill Patients with COVID-19

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 74-LB
Author(s):  
JOI HESTER ◽  
GEORGIA M. DAVIS ◽  
FRANCISCO J. PASQUEL ◽  
MARINA RABINOVICH ◽  
NORMA POINDEXTER ◽  
...  
Keyword(s):  
Real Time ◽  
Critically Ill ◽  
Continuous Glucose Monitoring ◽  
Critically Ill Patients ◽  
Glucose Monitoring ◽  
Glucose Sensing ◽  
Interstitial Glucose

Biocompatibility of an Electrochemical Sensor for Continuous Glucose Monitoring in Subcutaneous Tissue

2005 ◽  
Vol 7 (1) ◽  
pp. 163-173 ◽  
Author(s):  
A. Mang ◽  
J. Pill ◽  
N. Gretz ◽  
B. Kränzlin ◽  
H. Buck ◽  
...  
Keyword(s):  
Electrochemical Sensor ◽  
Continuous Glucose Monitoring ◽  
Subcutaneous Tissue ◽  
Glucose Monitoring

scholarly journals Review of the Long-Term Implantable Senseonics Continuous Glucose Monitoring System and Other Continuous Glucose Monitoring Systems

2020 ◽  
Vol 15 (1) ◽  
pp. 167-173 ◽  
Author(s):  
Jeffrey I. Joseph
Keyword(s):  
Continuous Glucose Monitoring ◽  
Subcutaneous Tissue ◽  
Glucose Monitoring ◽  
Clinical Trial Data ◽  
Diabetes Patient ◽  
Glucose Levels ◽  
Study Results ◽  
And Performance ◽  
Patient Use

The article published by Kevin Cowart in this issue of the Journal of Diabetes Science and Technology (JDST) is a detailed overview of the clinical trial data and analysis used to demonstrate the safety and effectiveness of the Eversense continuous glucose monitoring (CGM) System for regulatory approval and clinical acceptance. The article describes the published study results for safety, accuracy, reliability, ease of insertion/removal, adverse events, and ease of diabetes patient-use for controlling their glucose levels short and long term. The author nicely compares Eversense CGM System safety and performance with the short-term subcutaneous tissue CGM systems being commercialized by Dexcom, Medtronic Diabetes, and Abbott Diabetes. This comparison may help the clinician define which type of patient with diabetes might benefit the most from the long-term implantable CGM system. The majority of studied patients describe a positive experience managing their diabetes with the Eversense CGM System and request implantation of a new sensor 90 or 180 days later.

Sign in / Sign up

Export Citation Format

Share Document